Edwards Lifesciences (EW) Tops Q3 EPS by 1c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts EW Hot Sheet
Price: $89.07 -1.13%
Revenue Growth %: +8.4%
Financial Fact:
Basic (in dollars per share): 0.66
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +8.4%
Financial Fact:
Basic (in dollars per share): 0.66
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.67, $0.01 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.57 billion.
GUIDANCE:
Edwards Lifesciences sees Q4 2024 EPS of $0.53-$0.57, versus the consensus of $0.60. Edwards Lifesciences sees Q4 2024 revenue of $1.33-1.39 billion, versus the consensus of $1.396 billion.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Therma Bright plans $420,000 non-brokered private placement
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
